Tempus AI (NASDAQ:TEM – Get Free Report) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued on Tuesday, MarketBeat reports. They presently have a $55.00 price objective on the stock, up from their previous price objective of $50.00. JPMorgan Chase & Co.‘s target price indicates a potential downside of 20.94% from the stock’s current price.
A number of other equities analysts have also recently issued reports on TEM. TD Cowen restated a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Piper Sandler restated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Guggenheim assumed coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 price target on the stock. William Blair lowered shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and a consensus price target of $59.27.
Read Our Latest Research Report on Tempus AI
Tempus AI Price Performance
Tempus AI (NASDAQ:TEM – Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.18). As a group, equities analysts anticipate that Tempus AI will post -6.15 EPS for the current year.
Insider Buying and Selling at Tempus AI
In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jennifer A. Doudna sold 1,320 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $90.00, for a total transaction of $118,800.00. Following the completion of the sale, the director now directly owns 36,011 shares of the company’s stock, valued at approximately $3,240,990. This trade represents a 3.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,583,467 shares of company stock valued at $130,542,311.
Hedge Funds Weigh In On Tempus AI
A number of hedge funds and other institutional investors have recently modified their holdings of TEM. ARK Investment Management LLC boosted its position in shares of Tempus AI by 132.1% during the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after acquiring an additional 3,141,487 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Tempus AI by 166.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its position in Tempus AI by 166.0% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. Franklin Resources Inc. lifted its position in Tempus AI by 240.5% during the fourth quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after purchasing an additional 1,950,862 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Tempus AI by 86,947.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company’s stock valued at $55,836,000 after purchasing an additional 1,651,996 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.
About Tempus AI
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Read More
- Five stocks we like better than Tempus AI
- How to Read Stock Charts for Beginners
- Institutions Signal Opportunty to Buy High-Yield Kraft-Heinz
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 3 Explosive Tech Stocks Breaking Out Right Now
- 3 Warren Buffett Stocks to Buy Now
- BigBear.ai: Is It Opportunity Knocking or a Trap Door?
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.